Metastatic osteosarcoma bowel perforation secondary to chemotherapy-induced tumour necrosis.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
26 Apr 2022
Historique:
pmc-release: 25 04 2024
entrez: 27 4 2022
pubmed: 28 4 2022
medline: 29 4 2022
Statut: epublish

Résumé

Osteosarcoma is the most common paediatric and adolescent primary bone malignancy and is highly chemosensitive. Gastrointestinal metastases from osteosarcomas are rare. Bowel perforation secondary to chemotherapy is a potential serious complication reported in ovarian, colorectal and haematological malignancies. We report the first documented case of chemotherapy-mediated bowel perforation in an osteosarcoma patient with gastrointestinal metastases. A man in his 20s, with a history of resected osteosarcoma in remission, presented with abdominal pain. A computed tomography (CT) scan demonstrated a large calcified intrabdominal mass (15×13×9 cm) consistent with new peritoneal disease. After one cycle of palliative ifosfamide and etoposide chemotherapy, he developed a large bowel perforation and neutropenic sepsis consequently requiring resection of the perforated mass. Chemotherapy-induced bowel perforation is a rare but serious complication that should be considered in patients with osteosarcoma, and other chemosensitive malignancies, with intra-abdominal metastases. Recommencement of systemic therapies after bowel complications must be assessed cautiously on a case-by-case basis.

Identifiants

pubmed: 35473702
pii: 15/4/e247774
doi: 10.1136/bcr-2021-247774
pmc: PMC9045112
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Megha Bhadbhade (M)

Faculty of Medicine, UNSW, Sydney, New South Wales, Australia megha.bhadbhade@health.nsw.gov.au.
Department of Surgery, Bankstown Hospital, Bankstown, New South Wales, Australia.

Elizabeth Connolly (E)

Sarcoma Unit, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Sarit Badiani (S)

Faculty of Medicine, UNSW, Sydney, New South Wales, Australia.
Department of Surgery, Bankstown Hospital, Bankstown, New South Wales, Australia.

David Yeo (D)

Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Vivek Bhadri (V)

Sarcoma Unit, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH